scholarly journals Age at First Drink, Drinking, Binge Drinking, and DSM-5 Alcohol Use Disorder Among Hispanic National Groups in the United States

2014 ◽  
Vol 38 (5) ◽  
pp. 1381-1389 ◽  
Author(s):  
Raul Caetano ◽  
Britain A. Mills ◽  
Patrice A. C. Vaeth ◽  
Jennifer Reingle
2018 ◽  
Vol 5 (2) ◽  
pp. 205510291879270 ◽  
Author(s):  
F Michler Bishop ◽  
Jose Luis Rodriquez Orjuela

Approximately 64,000,000 people in the United States report binge drinking at least once in the past month. Unlike overeating and oversleeping, “overdrinking”—defined as drinking more than a person intends to drink—does not exist in the literature. Terms such as binge and problem drinking do not consider the intent of the drinker. The results of this pilot study suggest that most people drink more than they intend to drink. Moreover, they also report often being surprised that they overdrank. Smartphones may help overdrinkers be less often surprised by overdrinking and may prevent drinkers from developing an alcohol use disorder.


2021 ◽  
pp. 003335492110415
Author(s):  
Caitlin E. Martin ◽  
Anna Beth Parlier-Ahmad ◽  
Lori Beck ◽  
Anna Scialli ◽  
Mishka Terplan

Objectives Disparities in substance use disorder (SUD) treatment use persist across groups, including gender. Using a gender-informed approach to expand treatment capacity and reduce barriers to treatment engagement is vital. We examined SUD treatment need and receipt among people with SUD in the United States, by gender, and assessed gender-specific sociodemographic factors associated with unmet need for SUD treatment and reported treatment barriers. Methods We conducted an analysis of data among adults aged ≥18 with a past-year SUD from the National Survey on Drug Use and Health (2015-2018). We computed population-adjusted frequencies and proportions for SUD treatment need and receipt and assessed gender differences. Multivariate logistic regression assessed gender-specific sociodemographic variables associated with SUD treatment receipt. Results Among adults with a past-year SUD, 63.4% were men and 36.6% were women ( P < .001), only 10.6% received SUD treatment, and a greater percentage of women than men needed treatment for opioid use disorder (11.9% vs 9.9%; P = .002). Receipt of SUD treatment was lowest among women with alcohol use disorder followed by men with alcohol use disorder (7.5% vs 8.9%; P = .052). Non-Latinx Black men had fewer than half the adjusted odds of receiving SUD treatment than non-Latinx White men (adjusted odds ratio [aOR] = 0.44; 95% CI, 0.27-0.71). Latinx women (aOR = 0.37; 95% CI, 0.18-0.73) and non-Latinx Black women (aOR = 0.51; 95% CI, 0.27-0.94) had significantly lower odds of receiving SUD treatment than non-Latinx White women. Conclusions As public health efforts target expanding SUD treatment capacity and addressing disparities in use of SUD treatment, interventions informed by gender and culture should be prioritized.


2018 ◽  
Vol 75 (2) ◽  
pp. 211 ◽  
Author(s):  
Hui G. Cheng ◽  
Hamza Kaakarli ◽  
Joshua Breslau ◽  
James C. Anthony

2017 ◽  
Vol 74 (9) ◽  
pp. 911 ◽  
Author(s):  
Bridget F. Grant ◽  
S. Patricia Chou ◽  
Tulshi D. Saha ◽  
Roger P. Pickering ◽  
Bradley T. Kerridge ◽  
...  

2019 ◽  
Vol 5 (9) ◽  
pp. eaax4043 ◽  
Author(s):  
K. Witkiewitz ◽  
R. Z. Litten ◽  
L. Leggio

Alcohol is a major contributor to global disease and a leading cause of preventable death, causing approximately 88,000 deaths annually in the United States alone. Alcohol use disorder is one of the most common psychiatric disorders, with nearly one-third of U.S. adults experiencing alcohol use disorder at some point during their lives. Alcohol use disorder also has economic consequences, costing the United States at least $249 billion annually. Current pharmaceutical and behavioral treatments may assist patients in reducing alcohol use or facilitating alcohol abstinence. Although recent research has expanded understanding of alcohol use disorder, more research is needed to identify the neurobiological, genetic and epigenetic, psychological, social, and environmental factors most critical in the etiology and treatment of this disease. Implementation of this knowledge in clinical practice and training of health care providers is also needed to ensure appropriate diagnosis and treatment of individuals suffering from alcohol use disorder.


2021 ◽  
pp. 109110
Author(s):  
Thibaut Davy-Mendez ◽  
Varada Sarovar ◽  
Tory Levine-Hall ◽  
Alexandra N. Lea ◽  
Stacy A. Sterling ◽  
...  

2020 ◽  
Vol 21 (15) ◽  
pp. 1117-1138
Author(s):  
Falk W Lohoff

Alcohol use disorder (AUD) is highly prevalent and among the leading causes of morbidity and mortality in the United States. Pharmacotherapies for AUD are limited, thus making identification of patient subgroups that are most likely to respond favorably crucial. In this article, pharmacogenetic research on US FDA-approved and commonly prescribed off-label medications for the treatment of AUD is comprehensively reviewed. While the field has advanced in understanding pharmacotherapies for AUD and potential genetic moderators of treatment responses, the pharmacogenetic data to guide the prescribing clinician are limited and should be interpreted with caution. Precision medicine for AUD with more beneficial treatment responses and minimal side effects remains a high priority for further research.


Sign in / Sign up

Export Citation Format

Share Document